It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC

• Hoofdauteurs: Ken Akao (Auteur), Yuko Oya (Auteur), Takaya Sato (Auteur), Aki Ikeda (Auteur), Tomoya Horiguchi (Auteur), Yasuhiro Goto (Auteur), Naozumi Hashimoto (Auteur), Masashi Kondo (Auteur), Kazuyoshi Imaizumi (Auteur)
• Formaat: Boek
• Gepubliceerd in: Open Exploration Publishing Inc., 2024-07-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Despite innovative advances in molecular targeted therapy, treatment strategies using immune checkpoint inhibitors (ICIs) for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) have not progressed significantly. Accumulating evidence suggests that ICI chemotherapy is i...